Analyst to SpaceX Investors: You’re Valuing SpaceX Like AI Is Almost Worthless
A funny thing happened when Space Exploration Technologies (NASDAQ: SPCX) reported earnings this month. First, SpaceX declined 13.6%…
CNBC’s The China Connection newsletter: Piling into ‘human skills’ AI
The public and foreign visitors alike visit the World Robot Conference in Beijing on Aug. 21, 2026. Evelyn…
Microsoft Employees Reveal How Much Cash They’re Burning on AI
Microsoft employees aren’t just comparing salaries this year, they’re comparing how much AI they use. An internal spreadsheet…
ChatGPT vs. Gemini: Which Chatbot Is Better at Seeing the World Around You?
ChatGPT is the most well-known AI chatbot around, but Gemini has been gaining popularity for the past few…
Amazon’s Tetromino Project Aims to Fully Automate Delivery Stations
Amazon is developing a new generation of highly automated warehouses that use AI and robotics to process packages…
UK to use Ukraine battlefield data to train AI to protect sensitive sites | Defence policy
AI models trained on Ukrainian battlefield data will be used to stop protesters and foreign states targeting UK…
Nvidia senior manager linked to Supermicro scheme smuggling AI servers to China
That bill will likely face industry pushback, CNBC suggested, since cloud providers would bear the cost of that…
Japan to tap AI to speed up materials development 10-fold
The use of AI to discover new chemical compositions is gaining traction in the materials industry. (Nikkei illustration)…
Thomson Reuters Builds Thomson-1 AI Model to Rely Less on Anthropic
The Canadian data and legal giant Thomson Reuters wants to rely less on costly AI from Anthropic —…
Hugging Face reportedly in talks to be acquired for $13B
Hugging Face has been approached to sell at a valuation of $13 billion or more, Business Insider reported…
AI chatbot privacy goes beyond model training for ChatGPT and Meta
Mark Zuckerberg’s vision for Meta to ‘own’ AI space raises questions Meta CEO Mark Zuckerberg outlines his ambitious…
How AI is changing the pharmaceuticals landscape
Nintedanib, a widely used drug for pulmonary fibrosis, received official approval in 2014 after its development began in…